Latest Health News

Healthcare stocks split into two stories this week: big names sold off hard, while a few small caps ran on clear news. The biggest moves came from a sharp fall in Pro Medicus and Cochlear, while Noxopharm jumped after a top-tier journal publication.

ECP Emerging Growth Limited reported a 6.9% portfolio loss for H1 2025, underperforming the ASX Small Ordinaries Index, yet declared a fully franked interim dividend and teased a significant special dividend.

BTC Health’s investee, BTC Cardio, has landed exclusive Australian distribution rights for Jafron Biomedical’s hemoperfusion cartridges, aiming for a 2026 market debut pending regulatory approval.

Regal Asian Investments has announced a fully franked interim dividend of 8 cents per share, reflecting robust portfolio returns exceeding 30% over six months. The company also updates its dividend policy to focus on sustainable payouts tied to investment performance.

AVITA Medical reported an 11% increase in sales revenue for 2025, driven by deeper market penetration and new product launches, while reducing its net loss by 21%. The company secured a $60 million senior secured credit facility but flagged substantial doubt about its ability to continue as a going concern.

Alkane Resources has reported record-breaking financial and operational results for the first half of FY2026, driven by strong gold and antimony production across its expanded three-mine portfolio. The company’s robust cash flow and profit position set a confident tone for meeting full-year guidance.

Nick Scali Limited has announced a fully franked ordinary dividend of AUD 0.39 per share for the six months ending 31 December 2025, signalling steady returns for shareholders.

Nick Scali Limited has reported a robust half-year performance with a 36% rise in net profit, driven by strong sales growth and margin improvements in Australia and New Zealand, while UK operations show signs of recovery following extensive store refurbishments.

Ramsay Health Care has cleared a major regulatory hurdle with ACCC approval to acquire National Capital Private Hospital, setting the stage for completion in early fiscal 2027.

Cochlear Limited reported a modest 1% rise in sales but a 9% fall in underlying net profit for the half year ended December 2025, as the rollout of its innovative Nucleus Nexa System faced longer-than-expected regulatory and contract hurdles. The company anticipates a robust second half driven by broader product availability and service growth.

Cochlear Limited has announced an ordinary dividend of AUD 2.15 per share for the six months ending December 2025, with payments scheduled for April 2026 and options for currency conversion based on shareholder location.

Cochlear Limited posted a modest 1% increase in sales revenue for the half year ending December 2025, while underlying net profit fell 9%, impacted by cloud computing costs and a slower-than-expected Nexa System rollout. The company maintains its dividend and outlines cautious FY26 guidance.